Enzene Opens New Biomanufacturing Facility in Hopewell, NJ

Enzene, a global development and manufacturing organization based in India, has expanded its global biotech capabilities in the U.S. with the opening of a state-of-the-art biomanufacturing facility in Hopewell, NJ. The new 80,000-sq.-ft. facility represents Enzene’s first major manufacturing investment in the U.S. to support pharmaceutical innovation and supply chain resilience across North America. 

In addition to fed-batch drug substance manufacturing, the site leverages the company’s modular EnzeneX 2.0 platform, a fully connected continuous manufacturing (FCCM) technology. The platform is scalable and leverages optimized cell media and process analytical technology (PAT) to achieve 10-times the yield of conventional biomanufacturing, reducing the cost of goods sold to as low as $40 per gram.

“We are proud to bring our global expertise to the U.S. and contribute to the advancement of biopharmaceutical manufacturing,” added Himanshu Gadgil, Ph.D., CEO of Enzene. “Our first-to-market manufacturing technology is forging a new path in biologics manufacturing that will provide a cost-efficient, high yield, U.S.-based biomanufacturing solution for biopharmaceutical innovators, and complement our facilities in India to provide global supply solutions.”